Login to Your Account



Safety Stalls Transcept's Sleep Drug Again; Firm Awaits CRL

By Jennifer Boggs


Thursday, July 14, 2011
Apparently, it will take more than a next-day driving study to satisfy the FDA's concerns regarding the safety of Transcept Pharmaceuticals Inc.'s insomnia drug Intermezzo, a sublingual formulation of zolpidem that the Point Richmond, Calif.-based firm is hoping to position as the first sleep aid specifically for middle-of-the-night awakening.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription